

# EHA 2025 Congress

June 12–15, 2025  
Milan, Italy



## TOP ABSTRACTS

To help navigate the exciting content being presented at the 30th European Hematology Association (EHA) Congress, the AML Hub Steering Committee members have provided their recommendations of the top abstracts to look out for in AML.

# EHA 2025: Top abstracts in AML

June 12–15, 2025

## Thursday, June 12

Abstract	Title	Speaker
<b>S135</b> <a href="#">View</a>	All-oral decitabine-cedazuridine (DEC-C) + venetoclax (VEN) in patients with newly diagnosed acute myeloid leukemia (AML) ineligible for induction chemotherapy: Phase 1/2 clinical trial results	Gail Roboz
<b>S136</b> <a href="#">View</a>	Ziftomenib combined with intensive induction chemotherapy (7+3) in newly diagnosed <i>NPM1</i> -m or <i>KMT2A</i> -r acute myeloid leukemia (AML): Updated phase 1A/B results from KOMET-007	Harry Erba
<b>S137</b> <a href="#">View</a>	RP2D determination of bleximenib in combination with VEN+AZA: Phase 1b study in ND & R/R AML with <i>KMT2A/NPM1</i> alterations	Andrew Wei

## Saturday, June 14

Abstract	Title	Speaker
<b>S149</b> <a href="#">View</a>	Phase 3 study of intensive chemotherapy with or without dasatinib in patients with core-binding factor acute myeloid leukemia - final analysis of the AMLSG 21-13 trial	Hartmut Döhner
<b>S146</b> <a href="#">View</a>	Refinement of the ELN2022 prognostic subgroups in a real-life cohort of 1747 intensively treated adult AML patients of the PETHEMA registry	Joaquín Martínez-Lopez
<b>S267</b> <a href="#">View</a>	Allogeneic hematopoietic stem cell transplantation in AML patients treated with azacitidine and venetoclax: a retrospective multicenter real-life study by French Auraml group	Urbain Tauveron-Jalenques
<b>S268</b> <a href="#">View</a>	Impact of hypomethylating agents +/- venetoclax for the management of acute myeloid leukemia and myelodysplastic patients relapsing after allogeneic stem cell transplantation: A subanalysis on 308 patients of the GITMO AML/MDS-Relapse registry study	Michele Malagola

## Sunday, June 15

Abstract	Title	Speaker
<b>LB4005</b> <a href="#">View</a>	HCT frailty scale (HCT-FS) for assessing frailty in allogeneic hematopoietic cell transplant patients. Results from a multicenter and prospective Canadian and Spanish initiative	Maria Queralt Salas
<b>S140</b> <a href="#">View</a>	The combination of a <i>FLT3</i> -ITD, <i>NPM1</i> mut and an epigenetic regulatory gene mutation confers unique sensitivity to quizartinib: Analysis from the QuANTUM-First trial	Mark Levis
<b>S142</b> <a href="#">View</a>	Phase I/II study of decitabine, venetoclax, and quizartinib triplet combination in <i>FLT3</i> -ITD mutated AML	Musa Yilmaz
<b>S143</b> <a href="#">View</a>	Long-term follow-up of predominantly Asian patients with relapsed/refractory <i>FLT3</i> -mutated acute myeloid leukemia treated with gilteritinib versus salvage chemotherapy in the phase 3 commodore trial	Jaymini Patel
<b>S144</b> <a href="#">View</a>	A <i>CD33</i> -deleted allograft (Trem-cel) enables gemtuzumab ozogamicin maintenance post-hematopoietic cell transplant with therapeutic exposures and low toxicity in patients with acute myeloid leukemia	Guenther Koehne

Posters		
#	Title	Author
<b>PF473</b> <a href="#">View</a>	Ziftomenib in relapsed/refractory <i>NPM1</i> -mutant acute myeloid leukemia: Phase 1b/2 clinical activity and safety results from the pivotal KOMET-001 study	Amir Fathi
<b>PF474</b> <a href="#">View</a>	Long-term real-world experience with CPX-351 treatment for acute myeloid leukemia in England	Alexandrina Lambova
<b>PF480</b> <a href="#">View</a>	Final results of VEN A QUI trial: A phase I-II trial comparing venetoclax with low dose cytarabine or azacitidine combined with quizatinib in non-fit patients with acute myeloid leukemia	Juan Miguel Bergua Burgues
<b>PF486</b> <a href="#">View</a>	Time to treatment initiation and clinical outcomes in non-intensively treated adult acute myeloid leukemia: A PETHEMA-GPLA-ACHO-GRELAM registry study	Eduardo Rodríguez-Arbolí
<b>PF516</b> <a href="#">View</a>	Effect of mutation type and co-mutations on response to olutasidenib in patients with relapsed/refractory mutated <i>IDH1</i> AML	Stéphane De Botton
<b>PS1470</b> <a href="#">View</a>	Risk stratification of newly diagnosed acute myeloid leukemia treated with venetoclax in combination with intensive chemotherapy	Wei-Ying Jen
<b>PS1471</b> <a href="#">View</a>	A phase IB/2 trial of an all-oral “triplet” regimen for <i>IDH</i> -mutated myeloid malignancies: Decitabine/cedazuridine and venetoclax in combination with ivosidenib/enasidenib	Jennifer Marvin-Peek
<b>PS1480</b> <a href="#">View</a>	Phase II study of cladribine with low dose cytarabine and venetoclax alternating with azacytidine and venetoclax for newly diagnosed acute myeloid leukemia	Alex Bataller
<b>PS1482</b> <a href="#">View</a>	High efficiency of salvage therapy combining 7 days venetoclax and G-CSF, fludarabine, high-dose cytarabine, and mitoxantrone followed by allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute myeloblastic leukemia	Ahmad Ibrahim
<b>PS1483</b> <a href="#">View</a>	Primary results STIMULUS-AML1: A large, international, phase II study of sabatolimab combined with azacitidine and venetoclax as frontline therapy for unfit acute myeloid leukemia (AML) patients (pts)	Amer M. Zeidan
<b>PS1496</b> <a href="#">View</a>	Outcomes of adult patients with newly diagnosed <i>IDH</i> -mutated acute myeloid leukemia receiving intensive chemotherapy plus venetoclax	Jennifer Croden
<b>PS1536</b> <a href="#">View</a>	Allogeneic transplantation vs. chemotherapy as consolidation strategies in older acute myeloid leukemia patients after first complete remission: A systematic review and meta-analysis	Cilomar Martins de Oliveira Filho
<b>PS1540</b> <a href="#">View</a>	Prognostic impact of the AML60+ score for patients with acute myeloid leukemia treated with hypomethylating agents	Tobias Silzle
<b>PB2534</b> <a href="#">View</a>	Venetoclax-based regimens versus intensive chemotherapy as a bridge to allogeneic hematopoietic stem cell transplantation in patients with therapy-related acute myeloid leukemia	Ekaterina Romaniuk



**#EHA2025**

Follow us on X to keep up to date  
with the latest from the congress

**@AML\_Hub**



Brought to you by

